Lean body mass as a predictor of drug dosage. Implications for drug therapy.
about
A Review of the Toxicologic Implications of ObesityPharmacokinetics of drugs in cachectic patients: a systematic reviewCan lean body mass be used to reduce the dose of heparin and protamine for obese patients undergoing cardiopulmonary bypass?Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients.Estimation of lean body weight in older community-dwelling menPopulation pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteersDirect Determination of Lean Body Mass by CT in F-18 FDG PET/CT Studies: Comparison with Estimates Using Predictive Equations.Comparison of SUVs Normalized by Lean Body Mass Determined by CT with Those Normalized by Lean Body Mass Estimated by Predictive Equations in Normal Tissues.Pharmacokinetics of Antimicrobials in Obese Children.Revisiting the loading dose of amikacin for patients with severe sepsis and septic shockDetermination of dosing guidelines for stavudine (2',3'-didehydro-3'-deoxythymidine) in children with human immunodeficiency virus infectionGastro-oesophageal reflux disease in obesity: pathophysiological and therapeutic considerations.Relationships among liver and kidney volumes, lean body mass and drug clearance.Correlation of abdominal fat ratio with hepatic CT enhancementWhat is the best size descriptor to use for pharmacokinetic studies in the obese?Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers.Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines.Angiotensin II type 1 receptor antagonists in the treatment of hypertension in elderly patients: focus on patient outcomes.Population-based input function and image-derived input function for [¹¹C](R)-rolipram PET imaging: methodology, validation and application to the study of major depressive disorderThe relationship between body composition and response to neoadjuvant chemotherapy in women with operable breast cancer.Pharmacokinetics of tacrolimus according to body composition in recipients of kidney transplants.Defining sarcopenia: the impact of different diagnostic criteria on the prevalence of sarcopenia in a large middle aged cohortLean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens.Review of commonly used age-based weight estimates for paediatric drug dosing in relation to the pharmacokinetic properties of resuscitation drugs.Prevalence and prognostic effect of sarcopenia in breast cancer survivors: the HEAL Study.Nonnucleoside reverse transcriptase inhibitor pharmacokinetics in a large unselected cohort of HIV-infected women.Population Pharmacokinetic Analysis of Piperacillin/Tazobactam in Korean Patients with Acute InfectionsPopulation pharmacokinetics of recombinant human C1 inhibitor in patients with hereditary angioedemaPatient variation in veterinary medicine--part II--influence of physiological variables.The effects of obesity on drug pharmacokinetics in humans.Importance of lean body mass in the oncologic patient.Appendicitis in obese children.Population Pharmacokinetic Analysis of Doripenem after Intravenous Infusion in Korean Patients with Acute Infections.The Prevalence and Prognostic Value of Low Muscle Mass in Cancer Patients: A Review of the Literature.Levothyroxine Dosing Following Bariatric Surgery.Effect of Acetaminophen Ingestion on Thermoregulation of Normothermic, Non-febrile Humans.Population Pharmacokinetics and Pharmacodynamics Modelling of Dilmapimod in Severe Trauma Subjects at Risk for Acute Respiratory Distress Syndrome.Sarcopenia in gastric cancer: when the loss costs too much.Sex and race differences in QRS duration.Usefulness of standardized uptake value normalized by individual CT-based lean body mass in application of PET response criteria in solid tumors (PERCIST).
P2860
Q28082947-FBABFC92-4542-499C-8026-E39F27ADDE8FQ28535322-7C98AFE7-0D0E-4F93-A75F-DE6838194304Q33368055-18E0E05C-25DC-4671-9E65-56DF2F54CB6BQ33418378-6A456208-7117-4436-B8F8-8B1C34946194Q33668185-3B8B6F3B-AD72-4116-9F39-17723CB5DC34Q33676387-ACD57435-D43B-4515-BFCE-04A29D2E7F6FQ33700964-77BDB5C1-158D-4EBC-BD60-DF3293396947Q33704523-CEB90BFF-F776-4D27-95ED-F1A2747472BFQ33855312-A8C49D24-C542-4C19-940D-695CF9E7C8ECQ33919190-A4C5B9C8-F5E1-4678-9D2D-BE725BE0BADFQ33981606-6D762134-79A3-4656-BB40-35D6E21C3929Q34742027-16BF3900-A5E8-47EB-84E0-0711A5617820Q35802646-055633D6-D68E-4005-AB1F-AA8D422DF66BQ35803137-AA2C859F-D0C1-4244-81DA-9BAB1F7AE4F4Q35826324-77131DC0-9385-4250-9791-EFC67F3E50E3Q35878860-85A05BE4-AA45-448C-9E65-6469B5F172EBQ36018761-3CABFDEA-666B-4244-B191-D217A265F37FQ36160619-11B2E209-F4C6-46F1-A721-BCBD01D85C2EQ36319736-1CE90B26-094D-400F-A3DC-E12A49F79290Q36349579-71934FB0-80F0-4AFE-88E6-46D9BAABE031Q36471782-C0E86296-2675-4958-BBC8-F2C687512743Q36795241-DB99F57D-974B-4737-B7F9-11118D5EE1E7Q36797250-F0DC6BF5-AF68-4945-A40E-804D0D77C4AEQ36806593-D9253F7A-9DB0-4386-9121-5B093FBC9500Q37106252-72808442-8D99-4071-BACE-E9E55C25C4F6Q37237006-B911CEB0-4C5F-49F2-870C-59E4FC35CC2AQ37306664-8FC72192-1EAF-4E0B-895E-340005B0C905Q37353438-FA0E4773-B8F8-4391-BF7C-2A1631347CEFQ37810325-24920350-2BB7-45E6-92C2-B27B000064CCQ37854751-50984167-4B55-4225-8863-6ECA6AC902A7Q38035164-69CEF7C6-A650-4A70-9769-DD21BEA1E7A6Q38087908-2B8208CA-C31C-4348-985E-699E4303CB29Q38405565-1BE97EBF-DEF3-49E3-8F70-A5B4FDB8C745Q38842194-A8704A6E-BE49-4398-95B4-67E5EC84E419Q38913694-63EFE39C-2ECA-490A-9AFF-D4A58C78F85CQ38961118-15095855-F9E8-4A7D-8E78-04BE32AC3A31Q39076026-984B01A7-F18A-4BF8-B8CC-1EB30723B31EQ39287062-4E0EC9D6-EF8D-4148-B86A-7B601E99A58AQ39797978-C719A68E-89D7-461E-80A9-80F2AAD1C5DBQ40000275-9E355A31-46F4-43C3-8278-B3E075E015A8
P2860
Lean body mass as a predictor of drug dosage. Implications for drug therapy.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Lean body mass as a predictor of drug dosage. Implications for drug therapy.
@en
type
label
Lean body mass as a predictor of drug dosage. Implications for drug therapy.
@en
prefLabel
Lean body mass as a predictor of drug dosage. Implications for drug therapy.
@en
P1476
Lean body mass as a predictor of drug dosage. Implications for drug therapy.
@en
P2093
P304
P356
10.2165/00003088-199426040-00005
P577
1994-04-01T00:00:00Z
P6179
1017629041